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S210 Poster Session IConclusions:Near 50% of patients with refractory or relapsed HD
can be successfully treated with high dose chemotherapy and autol-
ogous stem cell transplantation.
It is important to have a longer follow up on these patients so we
can perform analysis on prognostic factors for relapse and survival.140
EVALUATING EFFECTIVENESS OF CHANGING THE ADMINISTRATION
TIME OF PLERIXAFOR ON PERIPHERAL CD 34 + CELL COUNTS
Johnson, M., Sirilla, J., Elder, P. OSU Medical Center-James Cancer
Hospital, Columbus, OH
Plerixafor has been shown to rapidly increase CD 34+ cells in
healthy volunteers alone or in combination with Neupogen (Fowler,
et al, 2009). The addition of Plerixafor to Neupogen results in a tri-
pling of circulating CD34+ cells 10 hours after administration
(Clerq, 2009).
At TheOhio State UniversityMedical Center-James CancerHos-
pital, we initially administered Plerixafor at 10 p.m. (10 hours prior
to the start of Apheresis). Administering Plerixafor at this time cre-
ated some issues requiring attention. First, there is the issue of incon-
venience to the patient. The patient would come to the hospital at
9:45 p.m., get their dose, go home or to a local hotel, then return
to the hospital for Apheresis at 7:30 a.m. the followingmorning. Sec-
ondly, because the outpatient clinic closed at 5:00 p.m., the patient
would go to the inpatient unit and have the charge nurse administer
the Plerixafor. At times, the inpatient unit had no available rooms to
see the patient and observe for side effects, becoming a concern for
the inpatient nursing staff to monitor the patient appropriately. Be-
cause of these issues, our institution changed the administration time
of Plerixafor to 6:15 p.m. The outpatient clinic adjusted their clinic
hours to accommodate the need for patients receiving Plerixafor.
Currently, we have administered Plerixafor to 24 patients (2 pa-
tients were remobilized with Plerixafor) since the drug received
FDA approval in December, 2008. Nineteen patient received Plerix-
afor at 10 p.m. Of these, sixteen patients had an adequate peripheral
CD 34+ count (.10) allowing them to collect an adequate amount of
stem cells for transplant. Of the 5 patients that received Plerixafor at
6:15 p.m., 4 patients had an adequate peripheral CD 34+ cell count
to proceed to Apheresis.
Changing the time of Plerixafor to 6:15 p.m. aided in the overall
safety of the patient. It is less inconvenient for the patient to return
to the hospital in the early evening (during daylight hours) and it al-
lows for the outpatient nursing staff to address any issues in an appro-
priate setting.
Our institution is looking at other areas of improvement using
Plerixafor. We are currently using an algorithm in determining
which patients may not mobilize an adequate number of CD 34+
cells. Also, we are checking the peripheral CD 34+ cell count on
day 4 of Neupogen in patients that are coming to the hospital to
have their central line placed to assess the need for Plerixafor that
evening.141
NEED OF RECONSIDERATION OF MOBILIZATION STRATEGY IN AUTOLO-
GOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: RE-
SULTS OF THE POSITIVE IMPACT OF HIGH NUMBER OF
CD34 + INFUSED CELLS
Michallet, M.1, Sobh, M.1, Nicolini, F.E.1, Raus, N.1, Baracco, F.1,
Cannas, G.1, Chelghoum, Y.1, Clapisson, G.1, Thomas, X.1, Troncy, J.1,
Ducastelle, S.1 1Edouard Herriot Hospital, Lyon, France
This study concerned 130 MM patients who underwent ASCT in
our center between years 2000 and 2007. There were 79males and 51
females with a median age of 56.8 years (34-72). Before transplanta-
tion, all patients received granulocyte-colony stimulating factor (G-
CSF) 5mg/kg/day, PBSC were mobilized in steady state in 135 cases,
62 after G-CSF + cyclophosphamide. As conditioning, all pts re-
ceived melphalan alone with a median total dose of 304 mg (130-
440). Sixty six patients received a single ASCT and 64 patients re-
ceived 2 ASCT in a double ASCT program. After transplantation,there were 2 graft failure, 40% of patients received red blood cell
(RBC) transfusions (median number: 0 [0-23]), and 64% received
platelet transfusions (median number: 1 [0-20]). Themedian number
of days with neutrophils\0.5 G/L was 6 (0-33) and with platelets
\20 G/L was 17 (2-104). The median length of hospitalization for
auto transplantation was 18 days (14-54). To assess the impact of
the infused CD34+ cells number, we have analyzed 2 groups: group
1 (n5 86) for ASCT with a number of CD34 +#3106/kg and
group 2 (n5 107) for ASCT with a number of CD34 +.3106/kg.
Results:We found a high significant impact of the high number of
infused CD34+(group 2) on platelets recovery (p5 0.002). The uni-
variate analysis using Cox model, showed a trend for the high num-
ber of infused CD34+ cells (group2) on leukocyte recovery
O.R5 0.748 [0.5-1.0] (p5 0.0568) and a high significant impact of
the same group on neutrophils recovery O.R5 0.670 [0.5-0.9]
(p5 0.009). These results were not changed even after adjustment
on age also on the sequential number of the ASCT in the double
auto ASCT program. The multivariate analysis using Cox model,
studying the impact of CD34+ group, age, gender, poor prognostic
factors [high level of b2microglobulin and del(13)], mobilization
(G-CSF alone or G-CSF + cyclophsphamide), showed a significant
impact only of poor prognostic factors on overall survival
O.R.5 7.94 [1.0-59.2] (p5 0.04) and also on progression free sur-
vival (PFS) O.R.5 2.55 [1.1-5.7] (p5 0.024).
Conclusion:High level of infused CD34+ appeared to be very opti-
mal for hematological recovery after ATSC inMM, without any sig-
nificant impact on O.S and PFS. An economical study is running on
this population to assess the impact of this level on hospitalization
and treatment costs, results will communicated in the future142
REVIEWING THE STATUS OF BACKUP HEMATOPOIETIC STEM CELLS
(HSC) BANKING FOR MULTIPLE MYELOMA (MM) PATIENTS WHO ARE
ELIGIBLE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELLS TRANS-
PLANT (AHSCT) IN THIS POOR ECONOMY
Abidi, M.H.1,2, Woldie, I.L.1, Goveas, R.1, Ratanatharathorn, V.1,2, Al-
Kadhimi, Z.1,2, Abrams, J.1,2, Ayash, L.1,2, Lum, L.1,2, Uberti, J.1,2
1Wayne State University, Detroit, MI; 2Karmanos Cancer Center, De-
troit, MI
Novel drugs combinations have demonstrated response rates
similar to AHSCT. Due to lack of long term follow up, impact
of these novel agents on HSC mobilization is unknown. AHSCT
is still standard therapy for newly diagnosed MM. There are ran-
domized trials underway to better define the role and timing of
AHSCT in MM. Due to this uncertainty with novel agents, arbi-
trary recommendations are made to cryopreserve backup stem
cells for pts who want to postpone AHSCT & to collect addi-
tional HSC at 1st HSC collection for future use. There is no con-
sensus on minimum duration of HSC cryopreservation, and this
can create significant financial,legal & logistical issues for stem
cell laboratories.
Methods: From 03/2000 to 06/2009, 270 MM pts were evaluated
for AHSCT at Karmanos Cancer Center, Detroit, MI. This review
was conducted to determine utilization of cryopreserved HSC for
a 2nd AHSCT at relapse/progression. No stem cells were collected
if the intent was not to offer AHSCT. Storage time was calculated as
the time between 1st & 2nd BMTs; as time between BMT&death&
as time between BMT & last follow-up for those known to be alive.
Results: Two hundred and fifty two eligible pts had HSC stored
with the intent to immediately proceedwith at least a single AHSCT.
Seventeen pts (6.7%) received a 2nd transplant with progressive dis-
ease as the most common reason, tandem transplant and refractory
disease being other causes to perform delayed AHSCT. Significantly
more men than women received a second transplant. Differences in
age, race and stage of disease were not statistically significant. The
median CD 34+ cells dose collected was 8106/kg. A median 4.9
x106 CD 34+ cells/kg were infused; 26% (66/252) of pts had no cells
remaining after 1st transplant. Five (29%) of the 2nd transplants
were done during the 6months following the first transplant. The re-
mainder occurred between 51 and 92 months following first trans-
plant.
